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Abstract 
 
Background: Cancer is a disease that gets serious attention in the medical world. This is due to the ever increasing 
number of patients and there has been no effective way to treat. Cancer cells have telomerase activity is relatively high 
compared to normal cells, so the cancer cells have the ability to continue to proliferate. Cancer cells undergo 
uncontrolled mitosis and have high telomerase activity compared to cells normal. Telomerase is an enzyme responsible 
for telomere length, a segment of DNA that is the tip of chromosomes in eukaryotic cells. Telomeres are associated with 
the process of ageing and carcinogenesis. The purpose of this study was to determine the expression of telomerase in 
some cells such as breast cancer, cervical cancer, and lung cancer. Methods: The research method is experimental 
studies in several cancer cell cultures in the form of cell line. Cancer cells used were: HeLa (cervical cancer), MCF7 
and T47D (breast cancer), WiDr (lung cancer), and Raji (lymphoma) with culture medium RPMI, DMEM, and M199. 
Vero cells is used (fibroblast cells) as a control (normal cells). Expression of telomerase enzyme was measured by the 
Immunohystochemistry (IHC) method. Results: The results showed that the cancer cells have activity/higher 
telomerase expression were highly significant (p < 0.01) compared to normal cells (Vero cells). Similarly, the 
expression of telomerase in HeLa versus WiDr, WiDr versus T47D, T47D versus Raji, and Raji versus MCF7 also 
showed highly significant differences (p < 0.01). Telomerase expression between cancer cells that showed significant 
difference (HeLa cells versus Raji cells; HeLa cells versus MCF7 cell; T47D cells versus MCF7 cells) (p < 0.05). No 
significant difference was found in the group of HeLa cells versus T47D, WiDr versus Raji cells, and WiDr versus 
MCF7. Conclusions: It was concluded, that the cancer cells have telomerase expression of specific and different from 
each other, depending on the type of cell. T47D breast cancer cells have telomerase expression of the highest, followed 
by cervical cancer cells (HeLa). Lung cancer cells (WiDr) with cell lymphoma (Raji) has almost the same expression 
and both have lower expression. 
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Introduction 
 
Cancer is a process that occurs gradually include initiation 
(irreversible genetic changes) and promotion (population 
of cells which extends initiation) and eventually malignancy. 
It is known that the enzyme telomerase plays a role in 
every cell replication that is able to maintain long 
telomeres to offspring, so that when the cancer cells do 
not have sufficient telomerase enzyme, then the growth 
of cancer cells is stalled by itself.1,2 Of the several types 
of cancer, cervical cancer remains the most common 
cancer among women. It is the second major cause of 
women’s death in Asia as well as in Indonesia.3 
 
On the other side are known, genes contained in the 
DNA molecule of a chromosome in the cell nucleus. 
Segments of DNA on the ends of chromosomes known 
as telomeres and is one of the factors related to the 
occurrence of cancer. Telomeres consist of highly 
specific nucleotide sequence, the human sequence is 
TTAGGG is repeated hundreds or even thousands of 
times, so the formula is the nucleotide structure of 
telomeres (TTAGGG) n. T, A, and G show the nucleotide 
(DNA-forming compound collection) which contains 
thymin, adenine, and guanine bases. In humans there are 
2.000 repetitions on the base unit. In one organism in 
different cell types, any number of repetitions of 
different nucleotides.1,4 The length of telomeres play an 
important role in maintaining genome stability and 
regulate replication and cell death. In length or short 
telomere is maintained by the enzyme telomerase, 
which serves to lengthen telomeres and DNA damage 
repair. The exact shape of this enzyme may different 
from one species to another species, but each version 
has a specific template RNA subunit to form a new 
telomere.5,6 Telomerase activity in normal cells is mainly 
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found in the reproductive cells because these cells have 
unlimited proliferative power. Telomerase consists of two 
functional components, namely the telomerase reverse 
transcriptase (TERT, hTERT in humans) and telomerase 
RNA template.7,8 Telomerase activity is mainly regulated 
by hTERT gene that plays an important role in the growth 
and development of tumours through the maintenance 
of telomere length.8 
 
The presence of the enzyme telomerase in a variety of 
cancer cells each may give different expressions depending 
on the type or location of the cancer cell and telomerase 
is not found on normal cells. It can be used as the basis of 
treatment of cancer cells if there are materials/substances 
that can inhibit the activity of the enzyme telomerase. 
Cancer cells have a high mitotic activity because cancer 
cells undergo uncontrolled mitosis and have higher 
telomerase activity compared to normal cells. There are 
no reports or data more thoroughly on the enzyme 
telomerase expression in several different types of 
cancer cells. The purpose of this study was to determine 
the expression of telomerase in several types of cancer 
cells such as breast cancer, cervical cancer, and lung 
cancer by in vitro. 
 
Methods 
 
In this research, the enzyme telomerase expression was 
measured in cultured cancer cells (cell line) from breast 
cancer, cervical cancer, lung cancer, and lymphoma. 
The study consisted of six groups consisting of one 
group of normal cells (Vero) as control and five other 
groups are cancer cells (T47D, HeLa, WiDr, Raji, and 
MCF7). Telomerase expression was measured by using 
a technique Immunohystochemistry (IHC) and calculated 
the percentage of cells which showed positive 
expression. 
 
Materials. Materials used in this study were breast 
cancer cell line (T47D and MCF7), cervical cancer cell 
line (HeLa), lung cancer cell line (WiDr), and 
lymphoma cancer cell line (Raji). Also used a normal cell 
line (Vero) as a comparison. Whole cell line was 
obtained from the collection of the Laboratory of 
Parasitology, Faculty of Medicine, Universitas Gadjah 
Mada, Yogyakarta. The medium used is the medium 
Roswell Park Memorial Institute (RPMI) 1640 (Sigma) 
for cell Raji, T47D, HeLa, and WiDr; media Dulbecco's 
Minimum Essential Medium (DMEM) (Gibco) for cells 
MCF7 and medium M-199 (Sigma) for Vero cells. The 
materials for IHC are Fetal Bovine Serum (FBS) (Gibco 
BRL), Phosphate Buffer Saline (PBS), Sterptomisin 
penicillin (Merck), telomerase antibody (Sigma) (Dako 
Corporation), HEPES, SDS (Sodium Dodecyl Sulphate) 
(Dako Corporation). The tools used in the study include 
CO2 incubator (Inc 2 Memmert), autoclave (Cryolab 35), 
laminair cabinet irflow (LAF) (Lab Konko), microscope 
(Olympus), and tissue culture flasks (Nunclone). 
Preparation of Culture Media and Growing of Cells. 
Preparation of culture medium RPMI (Rosewell Park 
Memorial Institute) is to dissolve the powder to one liter 
of RPMI 1640 into akubides approximately 800 mL, 
plus 2 g of sodium bicarbonate and HEPES 2 g, was 
added to one liter of distilled water. The solution was 
stirred with a magnetic stirrer about 10 minutes until 
homogeneous, then neutralised with 1 N HCl to pH 7.2 
to 7.4. Media of cells growing made by mixing FBS as 
much as 19 mL, 2 mL Streptomycin penicillin, 
Fungizone 0.5 mL, then diluted using RPMI 1640 
culture medium to 100 mL. Furthermore, the solution 
was filtered with a filter polyethene sulfone in aseptic 
sterile 0.2 µm. Stored in the refrigerator by using a 
sealed bottle. 
 
Telomerase expression examination by Immunohysto- 
chemistry (IHC). Cell culture T47D, MCF7, HeLa, WiDr, 
Raji and Vero with density 104 orwell already attached 
to the coverslip performed immunohistochemical staining 
(IHC) in the laboratory of Parasitology, Faculty of Medicine, 
Universitas Gadjah Mada, Yogyakarta. Measurement 
procedure telomerase expression with IHC method, as 
follows: the cell culture coverslip that had been treated 
were incubated at 5% CO2 incubator, temperature of 
37 °C for 24 hours, taken and placed on a glass object 
(poly-l-lysine slides), fixation with acetone or methanol 
for 10 minutes at -20 °C. Then washed with PBS 3 x 5 
min, then dropped 0.3% H2O2 for 20 minutes. After that 
spilled with normal mouse serum (1:50) for 15 minutes, 
the liquid discharged (without washing), then sprinkled 
with primary antibody (telomerase) for 60 minutes. Wash 
in PBS 3 times each for 5 minutes, then incubated in 
secondary antibody biotin (biotinylated secondary antibody) 
for 5-10 minutes, washed with PBS 3 times each for 5 
minutes. Incubation in streptavidin-peroxidase enzyme 
for 5-10 minutes, washed with PBS 3 times each for 5 
minutes. Tetrahidrochloride deamino-benzidine incubation 
in chromogen (DAB) for 5-10 minutes with chromogen 
substrate ratio of 1:20, washed with distilled water. 
Preparations immersed in hematoxylin for 3-5 minutes to 
counterstain, washed with distilled water and dehydrated 
performed using 95% ethanol, then with xylene each for 
10 minutes. Further preparations spilled mounting media 
(Canada balsam) and covered with a glass cover. Telo-
merase expression was observed using a light microscope. 
Cells that express telomerase will give a brown color, 
whereas cells that did not express the will give a purplish 
blue color. 
 
Results  
 
Calculation of telomerase expression by IHC method is 
done by counting the number of cells that showed positive 
expression (brown nucleus and cytoplasm) of 100 cells 
were examined. Calculations performed with 3 samples. 
The results are expressed in percent. Percentage of 
positive expression values are presented in Table 1. 
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The percentage of positive telomerase expression in 
cancer cells showed high expression. ANOVA test results 
showed the highly significant difference (p < 0.01) 
between groups of cancer cells with normal cells or the 
control group (Vero cells), with a value of F = 178.489 
(Table 2). 
 
The expression of telomerase in cancer cells in this study, 
including breast cancer cells, cervical cancer, lung cancer, 
and lymphoma showed higher expression than normal 
fibroblast cells (Vero). Besides the magnitude of the 
expression of telomerase in cancer cells, respectively, 
differ from each other. The results of the multiple 
comparison test LSD (Least Significant Difference) 
between each group is presented in Table 3. Telomerase 
expression in all groups of cancer cells (HeLa, WiDr, 
T47D, MCF7, and Raji) results showed highly significant 
difference (p < 0.01) than the control group (Vero). In 
addition it is also showed highly significant difference 
(p < 0.01) among the group of cancer cells as between 
HeLa versus WiDr, WiDr versus T47D, Rajiv versus 
T47D, and MCF7 versus Raji. Telomerase expression 
was significant difference (p < 0.05) was found between 
HeLa versus Raji, HeLa versus MCF7, T47D versus 
MCF7, while between HeLa versus T47D, WDR versus 
Raji, and WiDr versus MCF7 showed no significant 
difference (p > 0.05). 
Discussion 
 
Telomerase is an ribonucleoprotein enzyme that maintains 
protective structure at the ends of eucaryotic chromosomes, 
called telomeres. Telomerase is a structure that is 
responsible for the maintenance of telomeres, a replication 
of nucleotides (TTAGGG) n. In most human somatic 
cells, for example fibroblasts, suppressed the expression 
of telomerase and telomeres shorten progressively at 
each cell division. In contrast, most of the tumor cells or 
human cancer cells expressing telomerase, resulting in 
telomere length is stable. These observations suggest that 
telomere maintenance is essential for the proliferation of 
tumor cells or cancer.9,10 Telomerase activity determine 
cell proliferation, both cancer cells and normal cells 
under conditions in vitro and in vivo.11,12 
 
Although telomerase activity in cancer cells increased 
their activity, but De Lange reported that cancer cells 
telomeres are shorter than the surrounding normal tissue. 
The researchers speculate that telomerase becomes activated 
after cells lose their ability to proliferate. Telomerase 
activity in the cancer cells will increase after a certain 
phase is when the cell loses some substance telomeric. 
Finally, the enzyme telomerase is activated to stabilize 
telomere, the cancer cells will be immortal cell, and there 
was a continuous cell proliferation.1 Telomerase plays a 
 
Table 1. The Average Value of the Percentage of Positive Telomerase Expression from Each Group 
 
No Control Group  (Vero) HeLa Group WiDr Group Raji Group T47D Group MCF7 Group 
1 5 77 74 67 86 74 
2 5 78 64 67 90 74 
3 3 90 64 67 90 73 
Mean 4.33 81.67 67.33 67.00 88.67 73.67 
SD 1.15 7.23 5.77 0.00 2.31 0.58 
 
 
Table 2. Anova Results of the Expression of Telomerase in between Groups 
 
 Sum of square Df Mean of square F Sig 
Between groups 
Within groups 
Total 
13781.778 
185.333 
13967.111 
5 
12 
17 
2756.356 
15.444 
178.469 0.000 
 
 
Table 3. Test of Multiple Comparisons (LSD) Percentage of Positive Telomerase Expression between Each Group 
 
Group Control group (Vero) HeLa WiDr Raji T47D MCF7 
Control 
(Vero)  ** ** ** ** ** 
HeLa   ** * - * 
WiDr    - ** - 
Raji     ** ** 
T47D      * 
MCF7      - 
*significant different at p < 0.05 
**there are very significant difference at p < 0.01 
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key in cell immortality and tumorogenesis. Telomerase 
is activated in 80-90% of human cancer cells and it is 
not found in normal somatic cells so it can be used as a 
marker in the diagnosis of cancer. Clinical trials for 
telomerase can be useful as a non-invasive method for 
the early detection and monitoring of cancer.13,14 
 
Most normal cells or somatic cells such as fibroblasts 
(Vero cells) have a limited ability to replicate is generally 
40 to 50 generations, then will stop dividing, because 
the normal cell undergo aging and apoptosis. This is 
determined by the presence of erosions or telomere 
shortening, since most normal human cells lacking 
telomerase activity in the presence of strict repression of 
transcription of human telomerase reverse transcriptase 
(hTERT). In normal somatic cells telomere shortening, 
including stem cells, which are intended for cell renewal. 
So a somatic cell has the aging program.5,7,12,15 The 
above results indicate that, despite the expression of 
telomerase in cancer cells is much higher than the normal 
cells, but in each of the cancer cells are not the same 
expression. Telomerase expression is different in each 
species and each type of cell will show different telomerase 
expression, as did the level of develop-ment.12,16,17 
 
Breast cancer cells showed the highest expression than 
other cancer cells. Previous research on breast cancer 
reported that telomerase activity is regulated by human 
telomerase reverse transcriptase gene (hTERT), which 
plays an important role in the growth and development 
of breast cancer cells (MCF-7 and MDA-MB-231) through 
the maintenance of telomere length.8 Whereas telomerase 
expression in normal cells have been found in the germ 
cells in the ovaries and testes, and stem cells. Whereas 
in adult somatic cells telomerase expression is very low 
or does not show any expression of telomerase.18 The 
enzyme telomerase plays a role in every cell replication 
that is able to maintain telomere length to cell 
derivatives, so that if cancer cells do not have sufficient 
telomerase enzyme, then the growth of cancer cells by 
itself is discontinued when the enzyme is no longer able 
to sustain long continuous telomere due to abnormal 
proliferation control. The absence of the enzyme 
telomerase can inhibit the growth of cancer cell division 
by transmitting so that shorter telomeres and die before 
making any further damage. However, if the cancer 
cells are able to synthesise telomerase that cancer cells 
will continue to proliferate and become immortal.12,19 
 
From the description and the results above showed that 
telomerase is active or high prevalence in cancer cells, 
so that telomerase can be an attractive therapeutic target. 
In recent years, many standard therapeutic agents used 
to treat cancer that acts as an anti-telomerase. Such as in 
breast cancer has been to development tamoxifen, trog-
litazone as anticancer agents that are anti-telomerase.6,20 
On the other hand is known, that cyclooksigenase 
enzyme-2 (COX-2) may play a role as well as a specific 
marker that could help determine the diagnosis of 
cancer. Over-expression of COX-2 plays an important 
role in the carcinogenesis process. It has been reported 
that the expression of COX-2 increased in some cancer 
cells, such as lung cancer and breast cancer. COX-2 
enzyme may increase cancer cell proliferation and 
resistance to apoptosis and suppression of COX-2 will 
cause apoptosis.21 Suppression of hTERT expression in 
cancer cells will also improve the process of telomere 
shortening, thus triggering cell senescence and 
apoptosis. The target telomerase or hTERT as a strategy 
in anticancer therapy, is relatively new. Inhibition of 
telomerase or hTERT alone has minimal clinical 
efficacy. Has conducted research for the targeting of 
treatment through a combination of telomerase or 
hTERT and COX-2 to work synergistically in killing 
cancer cells.7 In addition to the target in therapy, 
telomerase is also used as an attractive target for the 
diagnosis and prognosis of breast cancer. The results of 
the examination of telomerase may be a marker of breast 
cancer diagnostics and improve diagnostic accuracy. 
Estimates of telomerase activity in various variants of 
breast cancer may predict the clinical course of the 
disease and provide prognostic instructions for different 
variants of breast cancer.22 
 
Conclusions 
 
Cancer cells have telomerase expression of specific and 
different from each other, depending on the type of cell. 
T47D breast cancer cells have telomerase expression of 
the highest, followed by cervical cancer cells (HeLa). Lung 
cancer cells (WiDr) with cell lymphoma (Raji) has almost 
the same expression and both have lower expression. 
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